Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

This statistical report, co-authored with the UK Health Security Agency (UKSHA), reports childhood vaccination coverage statistics for England in 2023-24. Data relates to the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through UKHSA's ImmForm system.

Our statistical practice is regulated by the Office for Statistics Regulation (OSR). The OSR sets the standards of trustworthiness, quality and value in the Code of Practice for Statistics that all producers of official statistics should adhere to.

Provisional monthly uptake data for seasonal influenza and COVID-19 vaccines for frontline HCWs working in trusts, Independent Sector Healthcare Providers (ISHCPs), and GP practices in England.

Data is presented at national, NHS regional and individual trust levels.

View the pre-release access list for these reports.

These data describe pneumococcal polysaccharide vaccine (PPV) uptake for the survey year, for those aged 65 years and over.RationaleVaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Pneumococcal disease is a significant cause of morbidity and mortality. Certain groups are at risk for severe pneumococcal disease, these include young children, the elderly and people who are in clinical risk groups2. Pneumococcal infections can be non invasive such as bronchitis, otitis media or invasive such as septicaemia, pneumonia, meningitis. Cases of invasive pneumococcal infection usually peak in the winter during December and January. The pneumococcal polysaccharide vaccine (PPV) protects against 23 types of Streptococcus pneumoniae bacterium. It is thought that the PPV is around 50 percent to 70 percent effective at preventing more serious types of invasive pneumococcal infection2.Since 1992 the 23 valent PPV has been recommended for people in the clinical risk groups and since 2003, the PPV vaccination programme has expanded to include immunisation to all those aged 65 years and over in England1This indicator was judged to be a valid and an important measure of public health and was therefore included in the public health outcomes framework. Inclusion of these indicators will encourage the continued prioritisation and evaluation and the effectiveness of the PPV vaccination programme and give an indication of uptake at an upper tier Local Authority level. The vaccination surveys measure the proportion of eligible people that have received PPV at any time and the proportion that received PPV during the previous year, providing an opportunity to assess the delivery of the immunisation programme11 Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2013 to March 2014 [online]. 2015 [cited 2015 Mar]. Available from URL: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates 2 Pneumococcal infections, NHS Choices [online]. 2013 [cited 2013 Dec]. Available from URL: http://www.nhs.uk/conditions/vaccinations/pages/pneumococcal-vaccination.aspxDefinition of numeratorUKHSA provided UTLA level data. Clinical commissioning group (CCG) data is available from https://www.gov.uk/government/collections/vaccine-uptake#ppv-vaccine-uptakeDefinition of denominatorNumber of adults aged 65 years and over. Data from 2013 to 2014 are now available at source at a local authority level. Data prior to 2013 to 2014 were collected at a PCT level and converted to LA level for inclusion in PHOF using the criteria as defined below:Denominators for local authorities are estimated from denominators for PCTs. Denominators for PCTs include all people registered with practices accountable to the PCT, and no data are available to provide resident-based figures. Denominators for local authorities are estimated as follows: (For local authorities that have exactly the same boundary as a PCT, the PCT figure is used as it is the only estimate available for the residents of the PCT and local authority. For local authorities whose boundary is contained wholly within a single PCT, but is not equal to the whole PCT, the LA denominator is estimated as a proportion of the PCT figure, with the exceptions of Isles of Scilly, City of London, Rutland, Cornwall, Hackney and Leicestershire (see below). For local authorities whose boundaries include all or part of more than one PCT, the local authority denominator is estimated by aggregating the appropriate proportions of the denominators for the PCTs whose boundaries include part of the local authority. The appropriate proportions in cases ii and iii are defined according to the resident population (in the appropriate age group) in the calendar year overlapping most of the period of the indicator value (or the most recent available): resident population by Lower Layer Super Output Area were extracted and used to calculate the population resident in every LA PCT overlapping block.To calculate the denominator, each LA PCT overlap is calculated as a proportion of the PCT resident population, and then multiplied by the denominator for the PCT. A LA may overlap several PCTs: the appropriate portions of all the PCTs’ denominators are aggregated to give the denominator estimate for the LA. Expressed as an equation the denominator is calculated as follows: DenominatorLA = ∑ (DenominatorPCT × n/N) summed over all PCTs overlapping the LA where: DenominatorLA = Estimated denominator in the LA n = Population resident in the LA-PCT overlapping block N = Population resident in the PCT DenominatorPCT = Denominator in the PCT For Isles of Scilly, City of London and Rutland, no indicator data are presented (prior to 2013 to 2014), as the local authority makes up a very small proportion of the PCT, and estimates for the LAs based on the PCT figures are unlikely to be representative as they are swamped by the much larger local authority within the same PCT. The estimates for Cornwall, Hackney and Leicestershire local authorities are combined data for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland respectively in order to ensure that all valid PCT data are included in the England total.Denominators for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland are not combined for the 2019 to 2020 annual local authority level data."CaveatsThe pneumococcal vaccine uptake collection is a snapshot of GP patients vaccinated currently registered at the time of data extraction. The proportion of GP practices who provided data for the surveys are available from the uptake reports. Data will exclude patients who have received the vaccine but have subsequently died, patients who have since moved, or patients that are vaccinated but have not had their electronic patient record updated by the time of data extraction. Data for local authorities prior to 2013 to 2014 have been estimated from registered PCT level indicators. While the majority of patients registered with practices accountable to a PCT tend to be resident within that PCT, there are, in some PCTs, significant differences between their resident and registered populations. Therefore the estimates for LAs may not always accurately reflect the resident population of the local authority (LA). Please note that the PCT response rate should be checked for data completeness as this will have a knock on effect to the LA values.

The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

This dataset illustrates uptake inequalities of fourth doses of the coronavirus (COVID-19) vaccine using 2021 Census-derived demographic and socio-economic characteristics: age. sex, ethnicity, religion, socio-economic status and self-reported disability and health status.

Vaccination data are produced using linked data from Deaths registrations and Census 2021, National Immunisation Management Service, Hospital Episode Statistics and General Practise Extraction Service data for Pandemic Planning and Research.

Data may differ from weekly administrative vaccination data published by NHS England.

Coronavirus (COVID-19) vaccination rates for people aged 18 years and over in England. Estimates by socio-demographic characteristic, region and local authority.

This statistical report, co-authored with Public Health England (PHE), reports childhood vaccination coverage statistics for England in 2018-19. Data relates to the routine vaccinations offered to all children up to the age of five years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through PHE's ImmForm system.

The data in this resource represents the compilation and analysis of the intellectual property terms in the eleven publicly accessible advanced purchase agreements which were signed in 2020, i.e. prior to an approved vaccine being available, five concluded by the UK government and six by the EU Commission.

The agreements analysed are as follows (in chronological order of the date they were signed): EU & AstraZeneca (27 August 2020) – unredacted. UK & AstraZeneca (28 August 2020) – redacted. UK & Valneva (13 September 2020) – redacted. EU & Sanofi/GSK (16 September 2020) – redacted. UK & Pfizer/BioNTech (12 October 2020) – redacted. EU & Janssen (21 October 2020) – redacted. UK & Novavax (22 October 2020) – redacted. EU & Pfizer/BioNTech (11 November 2020) – redacted. UK & Moderna (16 November 2020) – redacted. EU & CureVac (17 November 2020) – redacted. EU & Moderna (4 December 2020) – unredacted.

According to the report undertaken by the National Audit Office published on the 14 December 2020, the UK the UK government had concluded, as of the 8 December 2020, five agreements with potential vaccine suppliers. National Audit Office, ‘Investigation into Preparations for Potential COVID-19 Vaccines’ (14 December 2020) https://www.nao.org.uk/reports/investigation-into-preparations-for-potential-covid-19-vaccines/ accessed 30 September 2022.

For access to relevant documents related to the EU Vaccines Strategy see https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/public-health/eu-vaccines-strategy_en accessed 30 September 2022.

Copies of each agreement are also on file with the authors and are available on request.

Between January 1, 2021 and May 31, 2022, there were approximately 30.6 thousand deaths involving COVID-19 among 80 to 89 year olds in England, with over 14 thousand deaths occurring among unvaccinated people in this age group. Across all the age groups in the provided time interval, deaths involving COVID-19 among the unvaccinated population was around double the amount of people who received at least two doses of a vaccine. For further information about the COVID-19 pandemic, please visit our dedicated Facts and Figures page.

Estimates of the association between coronavirus (COVID-19) vaccination and self-reported long COVID in people infected prior to vaccination, using data from the UK Coronavirus Infection Survey.

In December 2020, a survey carried out in the United Kingdom (UK) found that 87 percent of those aged 75 years of age were willing to take the COVID-19 vaccine and will take the vaccine as soon as it was offered to them. The highest support for taking vaccination was reported in the oldest age groups who are most at risk from the effects of contracting the coronavirus. On the other hand, 18 percent of those aged between 35 and 44 years said they did not want to be vaccinated and will do their best to avoid immunization, even if they were asked to do so by the NHS. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

United Kingdom UK: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 92.000 % in 2017. This stayed constant from the previous number of 92.000 % for 2016. United Kingdom UK: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 86.500 % from Dec 1980 (Median) to 2017, with 38 observations. The data reached an all-time high of 93.000 % in 2015 and a record low of 53.000 % in 1980. United Kingdom UK: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

The NHSBSA makes payments for Covid-19 vaccinations to Primary Care Network (PCN) providers in England. May I request the following data for the calendar months, January 2025, February 2025 and March 2025, individually by month and in excel format: Column 1 Year/month Column 2 ODS Code for PCN Column 3 Number of vaccinations claimed by the PCN Column 4 Number of vaccinations paid by the PCN Column 5 Total Payment made for administration of these Covid-19 vaccinations Column 6 Total of ALL other miscellaneous payments relating to Covid-19 vaccinations made to PCN. Response Column 2 - ODS Code for PCN I am writing to advise you that following a search of our paper and electronic records, I have established that we do not hold Primary Care Network (PCN) data that we can confidently join to the Lead PCN Practice ODS Code. Therefore, our data is at Lead PCN Practice level. Column 6 - Total of all other miscellaneous payments relating to Covid-19 vaccinations made to PCN. I am writing to advise you that following a search of our paper and electronic records, I have established that we do not hold information on miscellaneous payments. Remaining Information I can confirm that we hold the following information and a copy of this is attached: • Column 1 - Year/Month • Column 2 - ODS Code for Lead PCN practice level • Column 3 - Number of vaccinations claimed by the PCN • Column 4 - Number of vaccinations paid by the PCN • Column 5 - Total Payment made for administration of these Covid-19 vaccinations This information is at Lead PCN practice level as explained. Please read the notes to ensure your correct understanding of the data. Data source: NHSBSA Data Warehouse We calculate payments for Covid-19 vaccinations to pharmacies and Primary Care Network (PCN) groupings in England. Each month, vaccine providers submit claims to request payment based on the General Practice Enhanced Service Covid-19 vaccination programme specification ('the specification'). Data included in this request is limited to vaccinations carried out by PCN groupings only. Data included in this request is also limited to vaccinations administered in January, February and March 2025. The vaccine data is the latest held in the NHSBSA Data Warehouse. Both the number of 'claimed' and 'paid' vaccinations have been reported in this request. Vaccination records are limited to those which have been associated with a declaration submission; data with a valid declaration is shown as 'claimed'. These will be marked as 'paid', subject to the rules in the General Practice Enhanced Service Covid-19 vaccination programme specification ('the service specification'). Payments comprise an Item of Service (IoS) fee and potentially a Supplementary fee. Payments do not relate to the value of the drugs dispensed. Payment data includes payments made and those scheduled for payment in the future. We send payment files to Primary Care Services England for them to make payments to the PCN groupings and so we do not have information about the actual amounts paid. The total used for the payment calculation may not match the totals shown in 'live' POC systems or our Manage Your Service platform that continue to receive updates after the snapshot used to calculate payments was taken. Please note that some vaccinations attract a Supplementary fee, so it is not possible to determine the number of vaccinations by dividing the total paid by the basic IoS fee. This data does not include any adjustments made by our Provider Assurance team as part of any post payment verification exercise. These adjustments are made at account level and may relate to several months of activity. It is possible for new records from old administration months to be submitted to us by the contractor for processing in the future. Thus, the totals here for each administration month could change when more data is processed.

Estimates of the risk of hospital admission for coronavirus (COVID-19) and death involving COVID-19 by vaccination status, overall and by age group, using anonymised linked data from Census 2021. Experimental Statistics.

Outcome definitions

For this analysis, we define a death as involving COVID-19 if either of the ICD-10 codes U07.1 (COVID-19, virus identified) or U07.2 (COVID-19, virus not identified) is mentioned on the death certificate. Information on cause of death coding is available in the User Guide to Mortality Statistics. We use date of occurrance rather than date of registration to give the date of the death.

We define COVID-109 hospitalisation as an inpatient episode in Hospital Episode Statistics where the primary diagnosis was COVID-19, identified by the ICD-19 codes (COVID-19, virus identified) or U07.2 (COVID-19, virus not identified). Where an individual had experienced more than one COVID-19 hospitalisation, the earliest that occurred within the study period was used. We define the date of COVID-19 hospitalisation as the start of the hospital episode.

ICD-10 code

U07.1 :

COVID-19, virus identified

U07.2:

COVID-19, virus not identified

Vaccination status is defined by the dose and the time since the last dose received

Unvaccinated:

no vaccination to less than 21 days post first dose

First dose 21 days to 3 months:

more than or equal to 21 days post second dose to earliest of less than 91 days post first dose or less than 21 days post second dose

First dose 3+ months:

more than or equal to 91 days post first dose to less than 21 days post second dose

Second dose 21 days to 3 months:

more than or equal to 21 days post second dose to earliest of less than 91 days post second dose or less than 21 days post third dose

Second dose 3-6 months:

more than or equal to 91 days post second dose to earliest of less than 182 days post second dose or less than 21 days post third dose

Second dose 6+ months:

more than or equal to 182 days post second dose to less than 21 days post third dose

Third dose 21 days to 3 months:

more than or equal to 21 days post third dose to less than 91 days post third dose

Third dose 3+ months:

more than or equal to 91 days post third dose

Model adjustments

Three sets of model adjustments were used

Age adjusted:

age (as a natural spline)

Age, socio-demographics adjusted:

age (as a natural spline), plus socio-demographic characteristics (sex, region, ethnicity, religion, IMD decile, NSSEC category, highest qualification, English language proficiency, key worker status)

Fully adjusted:

age (as a natural spline), plus socio-demographic characteristics (sex, region, ethnicity, religion, IMD decile, NSSEC category, highest qualification, English language proficiency, key worker status), plus health-related characteristics (disability, self-reported health, care home residency, number of QCovid comorbidities (grouped), BMI category, frailty flag and hospitalisation within the last 21 days.

Age

Age in years is defined on the Census day 2021 (21 March 2021). Age is included in the model as a natural spline with boundary knots at the 10th and 90th centiles and internal knots at the 25th, 50th and 75th centiles. The positions of the knots are calculated separately for the overall model and for each age group for the stratified model.

This statistical report, co-authored with Public Health England (PHE), reports childhood vaccination coverage statistics for England in 2019-20. Data relates to the routine vaccinations offered to all children up to the age of five years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through PHE's ImmForm system.

Children for whom the local authority is responsible who completed a booster course of diphtheria, tetanus, pertussis, polio (DTaP and IPV) vaccine at any time by their fifth birthday as a percentage of all children whose fifith birthday falls within the time period.RationaleA booster vaccine for diphtheria, tetanus, pertusiss and polio disease has been in the routine childhood immunisation programme since late 2001. It is currently offered at 3 year and 4 months or soon after. Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels. May also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children in LA responsible population whose fifth birthday falls within the time period who received a DTaP and IPV booster at any time before their fifth birthday.Definition of denominatorTotal number of children in LA responsible population whose fifth birthday falls within the time period. Coverage figures are supplied for patients registered with GPs based in that LA and for unregistered patients who were resident in that LA. The LA responsible population is therefore different from the estimated resident population figures produced by the Office of National Statistics (ONS) for each LA. For the COVER collection, the LA responsible population is usually derived from the population registers held on CHISs.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental and should be treated with caution as it is not an official statistic.Information on childhood immunisation coverage at ages one, two, and five is collected through the UK COVER collection by UKHSA. These aggregated data are collected from CHISs, computerised systems storing clinical records that support health promotion and prevention activities for children, including immunisation. In England, COVER data are collected for Upper Tier Local Authorities (LAs) using the COVER data collection form. These are established collections based on total populations, not samples.The number of CHIS systems has decreased from over 100 in 2015 to around 70 by mid-2017. As different phases of the digital strategy are implemented across the country, it is anticipated that there may be further temporary local data quality issues associated with the transition. Temporary data quality issues in some London COVER returns during 2017 to 2018 were observed in the quarterly COVER reports as the new Hubs became responsible for generating coverage data. Changes in vaccine coverage within London should therefore be interpreted with caution for the time being.Data are extracted directly from local population registers, and data issues are generally related to underestimation of coverage. There may be some overestimation of denominators due to children who have moved away remaining on the area register, which can lead to underestimates of coverage. In some areas, it is known that a small number of GPs do not submit vaccination data to the local CHIS, also resulting in underestimation of coverage. Using non-standardised data extraction methods could result in overestimated coverage.Caution should be exercised when comparing coverage figures over time due to occasional data quality issues reported by some data suppliers. Apparent trends could reflect changes in the quality of data reported as well as real changes in vaccination coverage. While this issue will be more apparent at the local level, it may also impact national figures. Similarly, some caution should be exercised when comparing coverage between different areas where data quality issues have been reported.